Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records
Claim this profileCapability statement (.md)

ADAPTIVE BIOTECHNOLOGIES CORPORATION

UEIDMW5BNQ331K9CAGE5SRQ2NAICS621511
  • SAM expired
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$1.5M
Awards on record
24
Contract vehicles
0
Verified credentials
0

SAM.gov registration expired

The registration expired on Nov 4, 2026. Federal awards require an active SAM.gov registration (FAR 4.1102), so confirm renewal before proposing this company as a team member.

View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI

About ADAPTIVE BIOTECHNOLOGIES CORPORATION

ADAPTIVE BIOTECHNOLOGIES CORPORATION is a SAM.gov-registered entity based in SEATTLE, WA 98109-4456. UEI DMW5BNQ331K9; CAGE 5SRQ2; primary NAICS 621511. Compliance posture not provided. SAM registration expired.
Headquarters
SEATTLE, WA 98109-4456

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIDMW5BNQ331K9
  • CAGE5SRQ2

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.
Is this your company? Claim it

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.
Is this your company? Claim it

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

Past performance

Recompete RadarLearn more about past performance
Prime awards from USAspending.gov (FPDS), synced nightly. Recompete windows use the potential end date (base plus all options).
36-month obligations
$1.5M
Awards on record
24
Top funding agencies
Defense Health Agency · National Institutes of Health · Department of Veterans Affairs

Awards

  • 75N98026P01882

    Recompete 6–12 mo: Potential end Sep 27, 2027 (10 months away)

    ADAPTIVE BIOTECHNOLOGIES CORPORATION:1186779 [26-010014]

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $38.9K
    Period of performance
    Sep 28, 2026 – Sep 27, 2027
    AI brief for award 75N98026P01882Bid team for the recompete of award 75N98026P01882

  • 36C26026P0708

    Recompete 6–12 mo: Potential end Aug 31, 2027 (9 months away)

    REFERENCE LAB TESTING PORTLAND OREGON

    Department of Veterans Affairs

    Obligated
    $19.5K
    Period of performance
    Sep 1, 2026 – Aug 31, 2027
    AI brief for award 36C26026P0708Bid team for the recompete of award 36C26026P0708

  • 36C24126N0614

    Recompete 6–12 mo: Potential end Jul 14, 2027 (8 months away)

    CLONOSEQ TESTING FOR BOSTON AND WEST HAVEN VA HCS

    Department of Veterans Affairs

    Obligated
    $35.1K
    Period of performance
    Jul 15, 2026 – Jul 14, 2027
    AI brief for award 36C24126N0614Bid team for the recompete of award 36C24126N0614

  • W81K0025CA004

    Recompete < 6 mo: Potential end Mar 13, 2027 (4 months away)

    CLONOSEQ FDA-CLEARED IN VITRO DIAGNOSTIC (IVD) TESTING SERVICES

    Department of Defense · Department of the Army

    Obligated
    $142.4K
    Period of performance
    Mar 14, 2025 – Mar 13, 2027
    AI brief for award W81K0025CA004Bid team for the recompete of award W81K0025CA004

  • HT001425P0034

    Recompete < 6 mo: Potential end Feb 27, 2027 (3 months away)

    CLONOSEQ HAS RECEIVED CLEARANCE FROM THE FOOD AND DRUG ADMINISTRATION FOR AN IN VITRO DIAGNOSTIC TEST SERVICE THAT DETECTS BLOOD CANCER IN…

    Department of Defense · Defense Health Agency

    Obligated
    $89.7K
    Period of performance
    Feb 28, 2025 – Feb 27, 2027
    AI brief for award HT001425P0034Bid team for the recompete of award HT001425P0034

  • 36C25026P0251

    Recompete < 6 mo: Potential end Dec 28, 2026 (1 month away)

    CLONO-SEQ TESTING.

    Department of Veterans Affairs

    Obligated
    $243.8K
    Period of performance
    Dec 29, 2025 – Dec 28, 2026
    AI brief for award 36C25026P0251Bid team for the recompete of award 36C25026P0251

  • 36C24125N0754

    Completed: Period of performance ended Jul 14, 2026

    CLONOSEQ TESTING FOR BOSTON AND WEST HAVEN VA HCS

    Department of Veterans Affairs

    Obligated
    $95K
    Period of performance
    Jul 15, 2025 – Jul 14, 2026

  • 75N93024P01158

    Completed: Period of performance ended Sep 22, 2025

    IMMUNO SEQUENCING SERVICE

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $22.3K
    Period of performance
    Sep 23, 2024 – Sep 22, 2025

  • 75N93025P01035

    Completed: Period of performance ended Jul 31, 2025

    IMMUNOSEQ MMTCRB SERVICE (DEEP), CATALOG# ISS20001, QTY: 16

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $16.6K
    Period of performance
    May 27, 2025 – Jul 31, 2025

  • 36C24125N0234

    Completed: Period of performance ended Jul 14, 2025

    CLONOSEQ TESTING FOR VISN 1

    Department of Veterans Affairs

    Obligated
    $5.9K
    Period of performance
    Dec 6, 2024 – Jul 14, 2025

  • 36C24124N0570

    Completed: Period of performance ended Jul 14, 2025

    CLONOSEQ TESTING FOR VISN 1

    Department of Veterans Affairs

    Obligated
    $11.7K
    Period of performance
    Jul 15, 2024 – Jul 14, 2025

  • HT001419C0006

    Completed: Period of performance ended Feb 28, 2025

    CLONOSEQ MINIMAL RESIDUAL DISEASE IN-VITRO DIAGNOSTIC ARRAY FOR THE DEPARTMENT OF PATHOLOGY AT WALTER REED NATIONAL MILITARY MEDICAL CENTER

    Department of Defense · Defense Health Agency

    Obligated
    $385.9K
    Period of performance
    Aug 29, 2019 – Feb 28, 2025

  • 75N93024P00315

    Completed: Period of performance ended Feb 7, 2025

    ADAPTIVE BIOTECHNOLOGIES CORPORATION (AMBIS #2208735) LAB TESTING, ADAPTIVE IMMUNOSEQUENCING AND DNA EXTRACTION SERVICE

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $13.2K
    Period of performance
    Feb 8, 2024 – Feb 7, 2025

  • 75N93024P01192

    Completed: Period of performance ended Dec 20, 2024

    ADAPTIVE BIOTECHNOLOGIES CORPORATION IMMUNOSEQ SEQUENCING SERVICES

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $14.7K
    Period of performance
    Sep 23, 2024 – Dec 20, 2024

  • 36C24123N0883

    Completed: Period of performance ended Nov 25, 2024

    CLONOSEQ TESTING FOR VISN 1

    Department of Veterans Affairs

    Obligated
    $9.8K
    Period of performance
    Jul 15, 2023 – Nov 25, 2024

  • 75N93024P00606

    Completed: Period of performance ended Sep 30, 2024

    SARS-COV-2 IMMUNOSEQUENCING TESTING SERVICES

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $61.2K
    Period of performance
    May 7, 2024 – Sep 30, 2024

  • 75N90024P00658

    Completed: Period of performance ended Sep 30, 2024

    ADAPTIVE BIOTECHNOLOGIES CORPORATION:1186779 [24-013767]

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $234.9K
    Period of performance
    Mar 17, 2021 – Sep 30, 2024

  • HT942524P0095

    Completed: Period of performance ended Aug 5, 2024

    ADAPTIVE IMMUNOSEQUENCING SERVICE

    Department of Defense · Defense Health Agency

    Obligated
    $76.2K
    Period of performance
    Jul 3, 2024 – Aug 5, 2024

  • 75N93024P00599

    Completed: Period of performance ended Jul 3, 2024

    IMMUNOSEQ MMTCRB SEQUENCING SERVICE (DEEP)

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $10.4K
    Period of performance
    May 3, 2024 – Jul 3, 2024

  • 75N93024P00415

    Completed: Period of performance ended Jun 6, 2024

    ADAPTIVE BIOTECHNOLOGIES (AMBIS #2212394) LAB TESTING, ADAPTIVE IMMUNOSEQUENCING AND LAB TESTING, TCRB SERVICE

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $13.4K
    Period of performance
    Mar 8, 2024 – Jun 6, 2024

  • 36C24122N0693

    Completed: Period of performance ended Jul 14, 2023

    CLONOSEQ TESTING FOR VISN 1

    Department of Veterans Affairs

    Obligated
    $9.8K
    Period of performance
    Jul 15, 2022 – Jul 14, 2023

  • 75N93021P01430

    Completed: Period of performance ended Jan 7, 2022

    DNA EXTRACTION SERVICES (IMMUNOSEQ)

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $20.7K
    Period of performance
    Sep 15, 2021 – Jan 7, 2022

  • 75N93021P00122

    Completed: Period of performance ended Jan 2, 2021

    IMMUNOSEQ MMIGH SERVICE (SURVEY) QTY. 48

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $12.9K
    Period of performance
    Dec 3, 2020 – Jan 2, 2021

  • 75N93021P00040

    Completed: Period of performance ended Dec 31, 2020

    IMMUNOSEQ EXTRACTION SERVICE

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $11.5K
    Period of performance
    Nov 2, 2020 – Dec 31, 2020

Contract vehicles

Learn more about GWACs, IDIQs and contract vehicles

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Browse vehicle holders

Proven teaming graph

Learn more about sub-award reporting (FSRS)
Who ADAPTIVE BIOTECHNOLOGIES CORPORATION has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.
See where agencies spend

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more about SBIR/STTR Phase IIIAbout SBIR/STTR (opens in a new tab)
Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
7 awards
Total awarded
$4,505,999
By phase
  • SBIR Phase I: 5
  • SBIR Phase II: 2
By agency
  • Department of Health and Human Services: 7
Active projects
0 projects
Projects whose contract end date is today or later.
Phase II ending within 12 months
0 projects
Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
By year
  • 2017: 1
  • 2014: 1
  • 2013: 3
  • 2011: 1
  • 2010: 1

Awards (most recent first)

  • Correlating TCR diversity to immune reconstitution after cord blood transplant

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $519,759

    Nov 1, 2016 – Oct 31, 2018

    Solicitation PA12-088 (2012) · Topic NHLBI

  • Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $244,699

    Solicitation PA13-234 (2014) · Topic NIAID · Research partner: Stub

  • Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $165,191

    Solicitation PA12-088 (2013) · Topic NCI · Research partner: Stub

  • Correlating TCR diversity to immune reconstitution after cord blood transplant

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $2,528,467

    Solicitation PA12-088 (2013) · Topic NHLBI · Research partner: Stub

  • SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $266,199

    Solicitation year 2013 · Topic NCI · Research partner: Stub

  • Correlating TCR diversity to immune reconstitution after cord blood transplant

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $148,999

    Solicitation PA10-050 (2011) · Topic NHLBI · Research partner: Stub

  • Development of T-cell receptor repertoire profiling as a diagnostic for T1D

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $632,685

    Solicitation PHS2010-2 (2010) · Topic NIDDK

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

FedRAMP offerings

Learn more about the FedRAMP Marketplace
Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.
Find FedRAMP-authorized companies

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Exclusions & screening

Exclusions about SAM.gov exclusionsScreening list about the Consolidated Screening List
Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026

GSA CALC+ rate benchmark

Learn more about GSA CALC+ labor rates
Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.
See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded

NAICS, PSC & socio-economic status

Learn more about NAICS size standards
Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 621511Medical LaboratoriesPrimary
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)

SAM.gov does not report this entity as small under any listed NAICS code.

Socio-economic status

No socio-economic certifications reported in SAM.gov.

Product & service codes (PSC)

No PSC codes reported.

Teaming preferences

Learn more about teaming agreements and joint ventures

This company has not published teaming preferences.

SAM.gov teaming eligibility: Not eligible to be proposed until the SAM.gov registration is active again.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Is this your company? Claim it

Corporate hierarchy

Affiliation & size about affiliation and size
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.

  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with ADAPTIVE BIOTECHNOLOGIES CORPORATION?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.

Claim this profileCapability statement (.md)